Entera Bio Ltd 's Cash & cash equivalent grew by 2251.07 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Entera Bio Ltd 's Quick Ratio to 354.04, above Entera Bio Ltd average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 74 other companies have achieved higher Quick Ratio than Entera Bio Ltd in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 558 to 1011.

Explain Quick Ratio?
How much Cash & cash equivalents ENTX�s has?
What are ENTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ENTX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-1.96 %	235.93 %	9.52 %	268.26 %	109.29 %
Y / Y Cash & cash equivalent Change	3001.04 %	4.15 %	-67.1 %	-17.92 %	23.99 %
Quick Ratio MRQ	354.04	3.5	6.09	6.59	11.19
ENTX's Total Ranking	# 1011	# 558	# 750	# 390	#
Seq. Current Liabilities Change	-76.79 %	376.44 %	-37.07 %	40.86 %	-20.46 %
Seq. Cash & cash equivalent Change	2251.07 %	173.36 %	-41.8 %	-17.1 %	-21.04 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 75
Healthcare Sector	# 375
Overall Market	# 1011

Quick Ratio Statistics
High	Average	Low
71.98	24.99	1.44
(Dec 31 2022)		(Dec 31 2018)

Financial Statements
Entera Bio Ltd 's Current Liabilities	$ 1 Millions	Visit ENTX's Balance sheet
Entera Bio Ltd 's Cash & cash equivalent	$ 266 Millions	Visit ENTX's Balance sheet
Source of ENTX's Sales		Visit ENTX's Sales by Geography

Cumulative Entera Bio Ltd 's Quick Ratio

ENTX's Quick Ratio for the trailling 12 Months

ENTX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	117.41 %	156.87 %	130.32 %	201.5 %	143.28 %
Y / Y Cash & cash equivalent TTM Growth	609.3 %	-20.2 %	-17.54 %	15.65 %	12.4 %
Quick Ratio TTM	50.22	5.41	8.8	11.41	15.39
Total Ranking TTM	# 3620	# 2956	# 2765	# 2259	#
Seq. Current Liabilities TTM Growth	-0.26 %	65.16 %	1.72 %	29.75 %	17.84 %
Seq. Cash & cash equivalent TTM Growth	826.62 %	1.47 %	-21.57 %	-3.82 %	4.25 %

Quick ratio ranking by company, industry and sector >> Back to ENTX Financial Strength Comparisons >> Go to Compare ENTX Quick Ratio to its Competitors

On the trailing twelve months basis ENTX Cash & cash equivalent more than doubled by 3001.04 % in Q3 2026 year on year, while Current Liabilities dropped to $1 millions, this led to increase in in Entera Bio Ltd 's Quick Ratio to 50.22, above ENTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Entera Bio Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2956 to 3620.

Explain Quick Ratio?
How much Cash & cash equivalents ENTX�s has?
What are ENTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 140
Healthcare Sector	# 866
Within the Market	# 3620

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.02	7.13	4.18
(Jun 30 2022)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Entera Bio Ltd	354.04	$ 265.883 Millions	$ 0.751 Millions
Cg Oncology Inc	100.74	$ 984.458 Millions	$ 9.772 Millions

Date modified: 2026-11-07T09:45:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.